Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.32 |
| ▸ | TDP2 | O95551 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29808658 | 1.00 | TRPM8 (0.40) | TRPM8SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL28825229 | 1.00 | TRPM8 (0.40) | TRPM8SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL30674901 | 1.00 | TRPM8 (0.40) | TRPM8SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL10124296 | 1.00 | TRPM8 (0.40) | TRPM8SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL31068984 | 0.85 | TRPM8 (0.40) | TRPM8SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL2627815 | 0.85 | TRPM8 (0.40) | TRPM8SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL26271641 | 0.79 | TRPM8 (0.37) | TRPM8SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL27140480 | 0.79 | TRPM8 (0.37) | TRPM8SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL23006312 | 0.79 | TRPM8 (0.37) | TRPM8SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL29857523 | 0.77 | NOS3 (0.45) | SMN1; SMN2KDM4EHSP90AA1HTTPDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120026068-A | Preparation method of (S) -1- (3-bromopyridine-2-yl) ethanol | 上海医药工业研究院有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-117625565-A | Preparation method of (S) -3-bromo-2- (1-methoxyethyl) pyridine | 上海锐康生物技术研发有限公司 | 2024-03-01 | — | — | CN | claimed |
| WO-2026106912-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12624053-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260070930-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2026-03-12 | — | — | US | disclosed |
| EP-4695233-A2 | SYNTHESIS OF RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4696316-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4695228-A1 | SYNTHESIS OF RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260042740-A1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4054719-B1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250388608-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-12-25 | — | — | US | disclosed |
| CN-114867735-A | RAS inhibitors | 锐新医药公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-114786777-A | RAS inhibitors | 锐新医药公司 | 2022-07-22 | — | — | CN | disclosed |
| US-20220105185-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2022-04-07 | — | — | US | disclosed |
| WO-2022060836-A1 | INDOLE DERIVATIVES AS RAS INHIBITORS IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2022-03-24 | — | — | WO | disclosed |
| WO-2022060583-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2022-03-24 | — | — | WO | disclosed |
| WO-2021257736-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2021-12-23 | — | — | WO | disclosed |
| US-20210130326-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| US-20210130369-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| US-20210130303-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070930-A1 | RAS INHIBITORS | KRAS, NRAS, RIN1 | TRPM8 4562/4885SMN1; SMN2 4241/4885MEN1 402/4885 |
| US-20260042740-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | TRPM8 4684/4885SMN1; SMN2 3810/4885MEN1 2432/4885 |
| US-12624053-B2 | Ras inhibitors | KRAS, NRAS, HMGCR | TRPM8 3852/4885SMN1; SMN2 4495/4885MEN1 573/4885 |
| US-20210130326-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | TRPM8 4209/4885SMN1; SMN2 3728/4885MEN1 815/4885 |
| US-20220105185-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | TRPM8 4209/4885SMN1; SMN2 3728/4885MEN1 815/4885 |
| US-20210130303-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | TRPM8 4209/4885SMN1; SMN2 3728/4885MEN1 815/4885 |
| US-20250388608-A1 | RAS INHIBITORS | KRAS, NRAS, HMGCR | TRPM8 3852/4885SMN1; SMN2 4495/4885MEN1 573/4885 |
| US-20210130369-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | TRPM8 4209/4885SMN1; SMN2 3728/4885MEN1 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.